Research on garlic capsule and selenium-vitamin A, vitamin B, vitamin C applied in therapy of acute hepatocellular damage in a rat model  by Akintunde, Jacob Kehinde & Bolarin, Olakunle Enock
HOSTED BY Contents lists available at ScienceDirect
Journal of Acute Disease 2015; 4(4): 298–304298Journal of Acute Disease
journal homepage: www.jadweb.orgPharmacology http://dx.doi.org/10.1016/j.joad.2015.06.008*Corresponding author: Jacob Kehinde Akintunde, Drug Metabolism and
Molecular Environmental Toxicology Research Laboratory, Biochemistry Unit,
Department of Biosciences and Biotechnology, College of Pure and Applied Sciences,
Kwara State University, Malete, P.M.B 1530, 340001, Ilorin, Nigeria.
Fax: +234 08064156056
E-mail: akintundejacob@yahoo.com
Peer review under responsibility of Hainan Medical College.
2221-6189/Copyright © 2015 Hainan Medical College. Production and hosting by Elsevier (Singapore) Pte Ltd. All rightResearch on garlic capsule and selenium-vitamin A, vitamin B, vitamin C applied in therapy of acute
hepatocellular damage in a rat modelJacob Kehinde Akintunde*, Olakunle Enock BolarinDrug Metabolism and Molecular Environmental Toxicology Research Laboratory, Biochemistry Unit, Department of Biosciences and Biotechnology,
College of Pure and Applied Sciences, Kwara State University, Malete, P.M.B 1530, 340001, Ilorin, NigeriaARTICLE INFO
Article history:
Received 1 Jun 2015
Received in revised form 5 Jun,
2nd revised form 12 Jun 2015
Accepted 15 Jun 2015
Available online 5 Aug 2015
Keywords:
Lisinopril
Garlic capsule
Selenium
Angiotensin-converting enzyme
inhibitors
Sub-acute
Hepatic cell damage
Adenosine triphosphate
RatABSTRACT
Objectives: To evaluate the toxicity of lisinopril in liver of male rats and its reversal
effect of garlic capsule (GAR) and selenium-vitamin A, vitamin B, vitamin C (SACE).
Methods: Thirty ﬁve adult male wistar rats were randomly assigned into 5 groups of 7
animals per group. Group I serves as the control, animals in Groups II, III, IV and V
received 28 mg/kg body weight of lisinopril via oral route. Group III was co-treated with
GAR at therapeutic dose of 250 mg/kg body weight per day. Group IV was co-treated
with SACE at dose of 500 mg/kg body weight. Lastly, group V was co-treated with
GAR and SACE at doses of 250 and 500 mg/kg body weight respectively, and the
experiment last for 8 days.
Results: Administration of lisinopril caused systemic toxicity in liver as well as adverse
histopathologic changes in the tested tissue. While GAR and SACE signiﬁcantly
(P < 0.05) reversed the toxic effects induced by lisinopril.
Conclusions: Collectively, the results suggest that therapeutic dose of lisinopril elicits
toxicity in male rats through induction of oxidative damage and depletion of cellular
adenosine triphosphate. The reversal effects of GAR and SACE during lisinopril treat-
ment suggest that these antioxidants may ﬁnd clinical application in cellular damage
involving ROS and adenosine triphosphate.1. Introduction
Lisinopril is one of the antihypertensive medications that
belong to the angiotensin-converting enzyme (ACE) inhibitor
group. The ACE inhibitors are considered ﬁrst line drugs for the
therapy of hypertension and are considered particularly helpful
in preventing the renal complications of diabetes and high blood
pressure[1]. ACE inhibitors are sometimes used even in patients
with relatively normal blood pressure for treatment of heart
failure and prevention of diabetic neuropathy[2,3]. Lisinopril
works by inhibiting a chemical process involving high amount
of salt and water in the body. It has been reported that less
salt and water decrease the blood volume, thereby making
blood arteries and veins ﬂow smoother[4–6]. Lisinopril,paradigm of ACE inhibitors acts on the mechanism that
narrows blood vessels, so that by blocking it, lisinopril causes
blood vessels to relax, allowing more blood to ﬂow in the
body[7,8]. However, patients who suffer from hypertension can
bring their blood pressure back to normal by recommending
the drug. This is imperative because excessive pressure will
damage the blood vessels and lead to cardiovascular diseases
(e.g. heart attack). Lisinopril is a commonly prescribed ACE
inhibitor and this type of medication is commonly used to
decrease blood pressure by the renin-angiotensin-aldosteron
system[9,10]. These inhibitors block the conversion of
angiotensin I to angiotensin II, which ultimately leads to the
reduction of blood pressure[11]. Other enzymes besides that
which converts angiotensin I to II may also be inhibited. This
may account for some of the side effects of the ACE inhibitors.
Lisinopril was approved for use by the Food and Drug
Administration in the United States and is currently one of the
most widely prescribed medications in clinical practice, with
more than 60 million prescriptions ﬁlled yearly[12–14]. Despite its
wide scale use, cases of clinically apparent acute liver injury and
deaths attributed to lisinopril complications have beens reserved.
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instances of acute liver injury after 1–4 years of therapy, a
distinctly unusual pattern of drug induced liver injury[17–19].
Other common side effects of lisinopril therapy include
dizziness, fatigue, headache, cough, gastrointestinal upset and
skin rash[20,21]. In addition, previous study had shown immuno-
allergic manifestations (rash, fever, eosinophilia) in patients
treated with lisinopril, in which; they develop no auto-anti-
bodies[22]. Lisinopril might cause mild hepatitis[23,24] and it was
also reported that lisinopril therapy showed sexual dysfunction
in hypertensive male patients therapeutically administered[13,25].
Several xenobiotics enter the body through gastrointestinal
tract and after absorption are transported by the hepatic portal
vein to the liver; thus the liver is the ﬁrst organ perfused by
drugs that are absorbed in the gut. To date, research has largely
concentrated on hepatic cells, since the liver plays a major role
in the metabolism of xenobiotics and consequently the primary
target of most toxic responses. More so, GAR and selenium
ACE might be useful in treatment of liver damage. Thus, the aim
of the present study was (a) to validate the evidence whether
therapeutic dose of lisinopril induces hepatotoxicity in rats (b) to
investigate the combination therapy of garlic capsule (GAR) and
selenium-vitamin A, vitamin B, vitamin C (SACE) against
lisinopril sub-acute induced hepatic damage (c) and possibly to
validate the underlying biochemical mechanisms of lisinopril
toxicity in liver as well as its prevention by GAR and/SACE.
2. Materials and methods
2.1. Chemicals and reagents
Lisinopril, GAR, SACE, epinephrine, glutathione (GSH),
5,5-dithio-bis-2-nitrobenzoic acid, hydrogen peroxide, tri-
chloroacetic acid and thiobarbituric acid were purchased from
Sigma (St Louis, MO, USA). All other reagents were of
analytical grade and were obtained from the British Drug
Houses (Poole, Dorset, UK).
2.2. Experimental protocol
Thirty ﬁve adult male wistar rats weighing approximately
200–220 g obtained from the Department of Biochemistry,
University of Ilorin, Nigeria were randomly assigned into 5
groups of 7 animals per group. They were housed in a plastic
suspended cage placed in a well ventilated rat house, provided
rat pellets and water ad libitum, and subjected to a natural
photoperiod of 12 h light and 12 h dark cycle. All the animals
received humane care according to the criteria outlined in the
Guide for the Care and Use of Laboratory Animals prepared by
the National Academy of Science and published by the National
Institute of Health. Ethic regulations have been followed in
accordance with National and institutional guidelines for the
protection of animal welfare during experiments[26].
Rats in Group I served as control and were administered
distilled water. Animals in Groups II, III, IV and V received
28 mg/kg body weight of lisinopril via oral route. Group III was
co-treated with GAR at therapeutic dose of 250 mg/kg body
weight per day. Group IV was co-treated with ACE at dose of
500 mg/kg body weight. Lastly, group V was co-treated with
GAR and ACE at doses of 250 and 500 mg/kg body weight
respectively, and the experiment last for a week. The animalswere fasted overnight and sacriﬁced by decapitation 24 h after
the last treatment, livers were removed and cleared of adhering
tissues, washed in ice-cold 1.15% potassium chloride and dried
with blotting paper.
2.3. Biochemical assay
The livers were homogenized in 50 mmol/L Tris–HCl buffer
(pH 7.4) containing 1.15% KCl and the homogenate was
centrifuged at 10000 r/min for 15 min at 4 C. The supernatant
was collected for the estimation of catalase activity using
hydrogen peroxide (H2O2) as substrate according to the method
of Clairborne[27]. Also, H2O2 level was estimated using the
method described by Clairborne[27]. Superoxide dismutase
(SOD) activity was determined by measuring the inhibition of
autoxidation of epinephrine at pH 10.2 at (30 ± 1) C
according to Misra and Fridovich[28]. Protein concentration was
determined by the method of Lowry et al.[29].
2.4. Reduced GSH assay
GSH was determined at 412 nm using the method described
by Jollow et al.[30].
2.5. Lipid peroxidation assay
Lipid peroxidation was quantiﬁed as malondialdehyde
(MDA) according to the method described by Ohkawa et al.[31]
and expressed as mmol/mg tissue.
2.6. Lactate dehydrogenase (LDH) assay
The liver homogenate was assayed for LDH activity using
commercially available kit (Randox Laboratories, UK). Assay
was carried out according to the manufacturer's instructions[32].
2.7. Histopathological evaluation
The livers were ﬁxed in 10% formalin. They were directly
dehydrated in a graded serious of ethanol and embedded in
parafﬁn. Thin sections, 5–6 mm, were cut by using a microtome,
mounted on albumenized glass slides and stained with eosin and
hematoxylen. Morphological examination of liver was done by
using an ocular micrometer scale under light microscope.
2.8. Statistical analysis
The results of the replicates were pooled and expressed as
mean ± SE. One-way ANOVA was used to analyze the results
and Duncan multiple tests was used for the post hoc[33]. SPSS
17.0 for windows was used for the analysis and the least
signiﬁcance difference was accepted at P < 0.05.3. Results
3.1. Hepatic biochemical indices
The effect of lisinopril, lisinopril plus GAR, lisinopril plus
SACE, and lisinopril plus SACE plus GAR on hepatic
biochemical indices were presented in Figures 1–3. Lisinopril
Figure 2. Effect of GAR and SACE on lisinopril-induced toxicity on AST
activity.
Results are expressed as mean ± SEM; n = 7; Bars with different superscript
letters are signiﬁcant (P < 0.05) different; LIS: Lisinopril.
Figure 4. Effect of GAR and SACE on lisinopril-induced toxicity on ac-
tivity of catalase in liver cells.
Results are expressed as mean ± SEM; n = 7; Bars with different superscript
letters are signiﬁcant (P < 0.05) different; LIS: Lisinopril.
Figure 1. Effect of GAR and SACE on lisinopril-induced toxicity on ALT
activity.
Results are expressed as mean ± SEM; n = 7; Bars with different superscript
letters are signiﬁcant (P < 0.05) different; LIS: Lisinopril.
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aminotransferase (ALT) by 75% compared with the control
group (Figure 1). Co-administrations of lisinopril with GAR,
SACE and GAR plus SACE signiﬁcantly (P < 0.05) decreased
the activity of ALT by 57%, 71% and 83.3% respectively
(Figure 1). In addition, lisinopril caused an increase in the
plasma activity of aspartate aminotransferase (AST) when
compared with the control group (Figure 2). Co-treatment of
lisinopril with SACE or GAR plus SACE signiﬁcantly
(P < 0.05) decreased the activity of this enzyme by 22.5% and
37.5% respectively (Figure 2). Similarly, co-administration with
GAR caused a decrease in the activity of plasma AST (Figure 2).
Furthermore, group of animals treated with lisinopril markedly
(P < 0.05) increased the plasma activity of alkaline phosphatase
(ALP) (Figure 3) by 54.2%, when compared with the controlFigure 3. Effect of GAR and SACE on lisinopril-induced toxicity on ALP
activity.
Results are expressed as mean ± SEM; n = 7; Bars with different superscript
letters are signiﬁcant (P < 0.05) different; LIS: Lisinopril.group. Conversely, co-management of lisinopril with GAR,
SACE and GAR plus SACE signiﬁcantly (P < 0.05) decreased
the activity of ALP by 37.5%, 48.6%, and 59.5% respectively
(Figure 3).
3.2. Antioxidant status in the liver
In order to explore the possibility that lisinopril interferes
with antioxidant defense system and thereby induces oxidative
damage to rat liver, the antioxidant level and markers of
oxidative stress were evaluated. The activity of catalase in the
post-mitochondrial fraction of rat liver was decreased signiﬁ-
cantly in the lisinopril-treated rats (P < 0.05) by 25%
(Figure 4). Co-administration of GAR or SACE signiﬁcantly
(P < 0.05) increased the activity of catalase by 20% and
16.67%, respectively (Figure 4). Correspondingly, co-
treatment with GAR plus ACE increased the activity of cata-
lase by 13.3%. The activity of SOD decreased signiﬁcantly by
88.2% in the animals treated with lisinopril compared with the
corresponding group of control animals (Figure 5). This
decrease was prevented by 400% on co-administration with
SACE. Treatment with GAR did not show reversal effect on
the activity of SOD (Figure 5). Whereas, co-management with
GAR plus SACE remarkably (P < 0.05) reversed the activity of
SOD by 561.8% increase (Figure 5).
3.3. Markers of oxidative damage
Administration of lisinopril caused a signiﬁcant decrease
(P < 0.05) by 60% in liver GSH, antioxidant protein, when
compared with the corresponding group of control animalsFigure 5. Effect of GAR and SACE on lisinopril-induced toxicity on ac-
tivity of SOD in the liver.
Results are expressed as mean ± SEM; n = 7; Bars with different superscript
letters are signiﬁcant (P < 0.05) different; LIS: Lisinopril.
Figure 8. Effect of GAR and SACE on LDH level of lisinopril-induced
hepatotoxicity rats.
Results are expressed as mean ± SEM; n = 7; Bars with different superscript
letters are signiﬁcant (P < 0.05) different; LIS: Lisinopril.
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Figure 6. Effect of GAR and SACE on lisinopril-induced toxicity on GSH
level of the liver cells.
Results are expressed as mean ± SEM; n = 7; Bars with different superscript
letters are signiﬁcant (P < 0.05); LIS: Lisinopril.
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GAR plus SACE non-signiﬁcantly (P > 0.05) elevated the GSH
to normal by 50%. GAR administration did not signiﬁcantly
modulate the level of this protein following treatment with
lisinopril. The levels of MDA, a maker of lipid peroxidation, in
the liver increased signiﬁcantly (P < 0.05) in rats treated with
lisinopril by 700%, relative to the control group (Figure 7).
Increased MDA levels were markedly (P < 0.05) reversed by the
administration of both GAR and SACE to the lisinopril-treated
rats (Figure 7) by 62% and 25% respectively. Also, co-
treatment with GAR plus SACE remarkably (P < 0.05)
reversed the increased oxidative damage (MDA level) by 43.8%.
3.4. Cellular adenosine triphosphate (ATP) in the liver
Lisinopril-treated group of animals signiﬁcantly (P < 0.05)
depleted the activity of LDH, key marker attributed to the pro-
duction of ATP in the liver by 26.67%, when compared to the
corresponding control group (Figure 8). The depleted activities
of LDH were increased by co-administration of GAR and SACE
to the lisinopril-treated animals (Figure 8) by 27.27% and
36.36% respectively. In the same vein, GAR plus SACE
administration noticeably (P < 0.05) modulate the activity of
this enzyme by 163.64% increase following treatment with
lisinopril (Figure 8).
3.5. Histopathology of the hepatic cells
Figure 9 illustrates the different histopathologic changes that
were observed in the liver of animals that were given variousFigure 7. Effect of GAR and SACE on lisinopril-induced toxicity on MDA
content of the liver cells.
Results are expressed as mean ± SEM; n = 7; Bars with different superscript
letters are signiﬁcant (P < 0.05) different; LIS: Lisinopril.treatments in this study. The hepatic cells were arranged regularly
and showed no visible lesions (Figure 9a). Administration of
lisinopril showed fewer hepatocytes with large, dark, single nu-
cleus (Figure 9b). Co-treatments with GAR and GAR plus SACE
were able to reverse these histopathologic changes induced by
lisinopril (Figure 9c–e). As such, showed no visible lesions
whereas, co-administration with SACE was unable to entirely
protect the histopathologic changes induced by lisinopril.Figure 9. Representative photomicrographs of liver from lisinopril, lisi-
nopril plus GAR, lisinopril plus SACE and lisinopril plus GAR plus SACE-
treated animals. (Magniﬁcation: 400×).
A: Control rat showing normal hepatic morphology; B: Rat treated with
lisinopril showing fewer hepatocytes with large, dark, single nucleus as
indicated by arrows; C: Rat treated with lisinopril plus GAR; D: Rat treated
with lisinopril plus SACE showing locally extensive foci of moderate
thinning of hepatic cords [cord atrophy], INH with very large, dark, single
nucleus; E: Rat treated with lisinopril plus GAR plus SACE; NH: Normal
hepatocytes; NVL: No visible lesions; INH: Increase in numbers of
hepatocytes.
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Lisinopril is prescribed as ACE inhibitor to decrease blood
pressure by the renin-angiotensin-aldosteron system, but sus-
pected to induce a number of biochemical disorders in animals
and humans[16,19,21,24]. The lisinopril-treated rats showed a
decrease in the total protein content of their hepatic supernatant
(data not shown). Co-administration of lisinopril with GAR and
SACE did not signiﬁcantly improve the protein content. This in
part shows that the decrease in protein content in rats treated
with lisinopril may not be due to oxidative stress, but through
the direct inhibitory effect of lisinopril on protein synthesis[34].
The rats administered with lisinopril had a signiﬁcant
(P < 0.05) increase in the plasma activities of AST, ALT and
ALP compared with their corresponding control groups. The
increased level of hepatic enzymes may indicate degenerative
changes and hypofunction of the liver[35,36]. In addition, a rise in
plasma level of hepatic enzymes is an indication of liver damage
especially when hepatic cells have undergone necrosis[37,38].
These enzymes are localized in periportal hepatocytes,
reﬂecting their role in oxidative phosphorylation and
gluconeogenesis and their plasma activities presumably
increase as a result of cellular membrane damage and
leakage[39]. They may also escape from parenchyma cells into
the blood stream where their presence can be detected in the
plasma. Thus, elevated levels of AST, ALT and ALP as
observed in blood circulation were indicative that anti-
hypertensive drug could mediate hepatic injury. This observa-
tion is consistent with the previous study, where patients that
were administered with lisinopril had elevation in serum ami-
notransferases and was linked to a case of acute liver
injury[15,16,24]. Conversely, co-treatment with GAR, SACE and
GAR plus ACE caused a signiﬁcant decrease in the plasma
ALT, AST and ALP suggesting that the drugs were able to
protect the liver from oxidative damage.
The animals treated with lisinopril in this study exhibited
decreased activities of antioxidant enzymes-SOD and catalase,
and also decreased levels of GSH in the liver. This decrease in
the antioxidant defense molecules led to a concomitant increase
in the level of MDA, a maker of hepatic lipid peroxidation. The
inactivation of the antioxidant enzymes may be caused by excess
ROS generated in the system[35]. SOD generally dismutases the
superoxide anion radicals into H2O2, which is readily
degraded by catalase and GSH peroxidase using reduced GSH.
Reactive oxygen metabolites such as singlet oxygen, hydroxyl
radicals, superoxide and H2O2 are known to be cytotoxic
agents because of their ability to induce lipid peroxidation in
tissue and membranes[40]. In the biological system, the
antioxidant enzymes catalase and peroxidases protect against
SOD inactivation by H2O2, while the SOD reciprocally
protects catalase and peroxidase against inhibition by
superoxide anion. Our data show that co-administration of
GAR, SACE or GAR plus SACE with lisinopril signiﬁcantly
attenuated the effects of this drug on the antioxidant enzymes
and further suggest that lisinopril could cause impairment to
hepatocytes through induction of oxidative stress. GSH plays a
central role in the detoxiﬁcation of xenobiotics and maintenance
of the redox status of the cells[36]. A decline in its cellular level
has been considered to be indicative of oxidative stress. This
observation is in agreement with the results of the present
study, where there was a decrease in GSH level in the liver of
lisinopril-treated rats. Furthermore, the protective effect ofselenium ACE may be attributed to the presence of selenium
(co-factor) which functions at the active site of seleno-enzyme
GSH peroxidase. GSH peroxidase not only allows the removal
of the toxic radicals but also permits the regeneration of lipid
molecules through re-acylation in the cellular membrane[41].
However, SACE may play an important role in the preventive
indication of hepatic cellular injury induced by lisinopril
therapy.
Hepatocytes have been considered to be highly vulnerable to
lipid peroxidation in the presence of elevated ROS levels, due to
the abundance of polyunsaturated fatty acids in their mem-
brane[35,36]. Increased lipid peroxidation and reduced level of
antioxidant capacity of the liver in lisinopril-treated rats in-
dicates an increased free radical generation and could be linked
to its effect on the hepatic cells. Increased ROS formation due to
lipid peroxidation and compromised antioxidant defense system
has been shown to be associated with hepatocellular dam-
age[35,36]. Co-administration of the antioxidants, GAR, SACE and
GAR plus SACE, signiﬁcantly prevented the increase while
treatment with GAR exhibited better and more signiﬁcant pro-
tection on hepatic lipid peroxidation. The high hepatoprotective
properties of the GAR might not be unconnected to the presence
of sulfur compounds (thiosulﬁnates), including allicin, as the
established active components in the root bulb of the garlic
plant. This active substance had been implicated as hepatic cells
restorer and/or healer[42,43]. In addition, garlic has long been used
medicinally, most recently for its cardiovascular, anti-neoplastic,
and clinical antimicrobial activities[44,45]. Studies had also shown
its signiﬁcant lipid-lowering effects in the liver and anti-platelet
activity[46,47]. Further study suggested that garlic has no effect on
drug metabolism[48,49].
LDH is an oxido-reductase enzyme that catalyses the inter-
conversion of pyruvate and lactate. Cells release LDH into the
bloodstreamafter hepatic damage. The level of cellularATP during
anaerobic conditions couldbe assessed usingLDHactivity because
it is a fairly stable enzyme[50]. As observed in the study,
administration of lisinopril signiﬁcantly depleted the activity of
liver LDH. Our data speculates that lisinopril would slow down
the metabolic pathways responsible for ATP energy production.
This ﬁnding supports the previous discovery that patients with
hepatic dysfunctions showed low levels of ATP[51,52]. Co-
administration of the antioxidants GAR, SACE and GAR plus
SACE signiﬁcantly prevented the decrease in LDH, while treat-
ment of lisinoprilwithGARplusSACEshowedabetter therapeutic
cure. This may be attributed to the additive and/or synergistic two-
fold performance of the antioxidants-GAR and SACE. More so,
high level of ATP production in the liver by selenium ACE
corroborated the ﬁnding of Schnell et al.[53] which reported that
selenium pre-treatment decreased the in vivo covalent binding of
acetaminophenmetabolites to hepatic protein. This caused increase
in the activity of gamma-glutamylcysteine synthetase which might
account for the increased GSH availability in selenium-treated
animals. Therefore, increase in the activities of GSH S-trans-
ferase and glucose-6-phosphate dehydrogenase will eventually
cause high ATP generation via glycotic pathway[54–56].
Adverse histopathologic changes showing fewer hepatocytes
with large, dark, single nucleus were observed following lisi-
nopril administration to the experimental rats. Co-treatments
with GAR and GAR plus SACE were able to reverse these
histopathologic changes induced by lisinopril. But, co-
administration with SACE was unable to entirely protect the
histopathologic changes.
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of therapeutic dose of lisinopril to male rats induced oxidative
stress by decreasing the antioxidant system. The lipid peroxi-
dation was increased with concomitant liver dysfunctions. The
mechanism is not unlinked to the lowering of cellular ATP
content and damage to the hepatic epithelial cells. GAR, SACE
and GAR plus SACE exhibited similarities in their capability to
alleviate the toxic responses of lisinopril, which suggests that the
adverse effects of lisinopril on the liver are at least in part due to
impairment of the antioxidant defense system, depleted cellular
ATP and further enhancement of lipid peroxidation. The
inability of these antioxidants to fully protect the liver against
lisinopril-induced toxicity suggests that the anti-hypertensive
drug could mediate hepatic damage through other mechanisms
apart from oxidative stress and oxidative phosphorylation. In
view of the importance of this drug in clinical practice, the
relevance of our study to humans merits further investigation on
other mechanisms (especially molecular mechanisms) by which
lisinopril induces hepatic damage.
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